PropThink: Upcoming Clinical Results for CHTP’s Northera Could Rejuvenate The Stock

[ACN Newswire] – By David MoskowitzAfter being decimated earlier this year on the FDA rejection of Northera, shares of Chelsea Therapeutics (NASDAQ:CHTP) could be rejuvenated as new Phase III results are expected to be … more

View todays social media effects on CHTP

View the latest stocks trending across Twitter. Click to view dashboard